CanBas

サイトマップ

お問い合わせ

ENGLISH

研究開発/R&D

研究開発/R&D

関係論文

Invited Publication

1. Compounds that Abrogate the G2 Checkpoint
"Checkpoint Responses in Cancer Therapy"
Dai, Wei (Ed.), Humana Press, 2008: 117-133

2. G2 checkpoint abrogators as anticancer drugs
Minireview, Mol Cancer Ther 2004 3: 513-519

Peer-Reviewed Publication(一部)

1. Phase I Studies of CBP501, a G2 Checkpoint Abrogator, as Monotherapy and in Combination with Cisplatin in Patients with Advanced Solid Tumors
Clin Cancer Res 2011; 17: 3431-3442

2. Cell cycle phenotype-based optimization of G2-abrogating peptides yields CBP501 with a unique mechanism of action at the G2 checkpoint
Mol. Cancer Ther. 2007 6: 147-153

3. Cdc25C interacts with PCNA at G2/M transition
Oncogene, Vol.21, 1717・1726, 2002

4. Involvement of the Interaction between p21 and PCNA for the maintenance of G2/M arrest after DNA damage.
J Biol Chem, Vol.276, No.46, 42971-42977, 2001

5. Sensitization of cancer cells to DNA damage-induced cell death by specific cell cycle G2 checkpoint abrogation.
Cancer Res., 59, 5887-5891, 1999

6. Hox11 interacts with PP1 and PP2A and disrupts a G2 check point.
Nature, 385, 454-458, 1997

Abstracts(一部)

1. Phase I studies of CBP501, a novel G2 checkpoint abrogator, alone and combined with cisplatin (CDDP) in advanced solid tumor patients (pts). 2008 ASCO Annual Meeting, Chicago, May 30 – June 3, 2008

2. CBP501, a novel cell cycle G2 checkpoint abrogator. Preliminary results of the initial phase I and pharmacokinetic (PK) / pharmacodynamic (PD) study in patients (pts) with advanced solid tumors.
18th EORTC-NCI-AACR, Prague, November 7-10, 2006

3. Pre-clinical analysis of CBP501, a novel G2 checkpoint abrogator. AACR 94th Annual Meeting, Toronto, April, 2003
(The meeting had been postponed to July at Washington D.C.)

4. Targeting G2 checkpoint by a novel peptide CBP501
Keystone symposia, "Molecular Targets for Cancer Therapy", Banff, 3/19-24, 2003

5. Selective cancer cell killing by a novel G2 checkpoint abrogating peptide. <2001 AACR Scholar-In-Training Award>
AACR 92st Annual Meeting, New Orleans, Mar, 2001

6. Anti-cancer therapy by specific abrogation of DNA damage-induced cell cycle G2 checkpoint using Chk2 inhibiting peptides.
Keystone Symposia, Cell Cycle 2001,
Taos, Jan 9-14. 2001

7. Killing cancer cells by targeted abrogation of cell cycle G2 checkpoint by peptide antagonists against Chk1/Cds1 kinases.
AACR 91st Annual Meeting, San Francisco, April 1-5, 2000

8. Cdc25C transiently replaces Wee1HU in PCNA/Cdc2/Cyclin B complex at the G2/M transition.
Keystone Symposia, "Cancer, Cell cycle and Therapeutics", Jan8-13th, 2000

9. Sensitization of cancer cells to DNA damage-induced cell death by specific cell cycle G2 checkpoint abrogation.
Keystone Symposia, "Cancer, Cell cycle and Therapeutics", Jan8-13th, 2000

10. Regulation of the genes involved in the G2 checkpoint in the G2 arrested Jurkat. Keystone Symposia "The cell cycle" Keystone, Cololado, Mar 27-Apr 2, 1998